Probabilitas Kumulatif Survival Vaksin Covid-19 pada Populasi di Kota Depok Tahun 2021
Cumulative Probability of Vaccine Covid-19 Survival in the Population of Depok 2021
Abstract
Latar Belakang: Vaksin COVID-19 telah melalui uji tahap 1 hingga 3 dan digunakan selama satu tahun sebagai upaya memberikan kekebalan kepada individu di Kota Depok.
Tujuan: Penelitian ini ingin mengetahui peluang untuk bertahan terhadap infeksi SARS-CoV-2 pada penerima setiap jenis vaksin.
Metode: Penelitian menggunakan kohort retrospektif dengan analisis survival menggunakan metode Kaplan Meier. Subjek adalah penduduk di Kota Depok yang menerima vaksin COVID-19 dari tanggal 13 Januari 2021 sampai 12 Januari 2022.
Hasil: Status Outcome di dapat dari data testing dan kasus di Kota Depok. Sebanyak 723.973 orang yang menerima vaksin, yang terdiri dari dosis tunggal, dosis ganda, dan dosis tambahan. Kelompok dengan risiko paling besar untuk terinfeksi adalah perempuan, kategori SDM kesehatan dan usia 19-35 tahun. Insiden terbesar ada pada kelompok umur pra lansia pada dosis tunggal (1,2%) dan kelompok umur lansia (>60 tahun) pada dosis ganda (1,6%). Probabilitas survival tertinggi terlihat pada dosis tunggal adalah Pfizer dan dosis ganda adalah Moderna. Probabilitas survival kumulatif terendah adalah 97,29% selama satu tahun pengamatan. Insiden rate lebih rendah, namun hazard ratio lebih besar pada dosis ganda dibandingkan dosis tunggal.
Kesimpulan: Lima jenis vaksin yang digunakan seperti AstraZeneca, Sinopharm, Moderna, Pfizer, dan Sinovac memberikan kekebalan yang baik dalam mencegah terjadinya infeksi pada individu.
References
Satuan Tugas Penanganan COVID-19. Data Vaksinasi COVID-19 (Update per 13 Januari 2022) [Internet]. 2022. Available from: https://covid19.go.id/berita/data-vaksinasi-covid-19-update-13-januari-2022
P2P Kemkes RI. Program Vaksinasi COVID-19 Mulai Dilakukan, Presiden Orang Pertama Penerima Suntikan Vaksin COVID-19. 2021; Available from: http://p2p.kemkes.go.id/program-vaksinasi-covid-19-mulai-dilakukan-presiden-orang-pertama-penerima-suntikan-vaksin-covid-19/
Satuan Tugas Penanganan COVID-19. Daftar Vaksin COVID-19 Yang Digunakan di Indonesia [Internet]. Available from: https://covid19.go.id/tentang-vaksin-covid19
Callaway E. Covid Vaccine Boosters: The Most Important Questions [Internet]. Nature. 2021. p. 178–80. Available from: https://www.nature.com/articles/d41586-021-02158-6
Dinas Kesehatan Kota Depok. Perkembangan Vaksinasi COVID-19 di Kota Depok [Internet]. 2021. Available from: https://dinkes.depok.go.id/User/news/update-cakupan-vaksinasi-covid-19-kota-depok-per-15-desember-2021
Dinas Kesehatan Kota Depok. Perkembangan COVID-19 di Kota Depok [Internet]. 2021. Available from: https://dinkes.depok.go.id/User/detail/update-covid-19-kota-depok-per-13-januari-2022
Gyeltshen K, Tsheten T, Dorji S, Pelzang T, Wangdi K. Survival Analysis of Symptomatic Covid-19 in Phuentsholing Municipality, Bhutan. Int J Environ Res Public Health. 2021;18(20).
Poland G, Ovsyannikova IG, Kenndey RB. SARS-CoV-2 Immunity: Review and Applications to Phase 3 Vaccine Candidates. Lancet [Internet]. 2020;396(January):19–21. Available from: https://doi.org/10.1016/ S0140-6736(20)32137-1
Fabiani M, Ramigni M, Gobbetto V, Mateo-urdiales A, Pezzotti P, Piovesan C. Effectiveness of the Comirnaty ( BNT162b2 , BioNTech / Pfizer ) Vaccine in Preventing SARS-CoV-2 Infection among Healthcare Workers , Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021. Eurosurveillance [Internet]. 2021;26(17):1–7. Available from: http://dx.doi.org/10.2807/1560-7917.ES.2021.26.17.2100420
World Health Organization. Who Sage Roadmap for Prioritizing Use of Covid-19 Vaccines [Internet]. Who. 2022. Available from: https://www.who.int/publications/i/item/who-sage-roadmap-for-prioritizing-uses-of-covid-19-vaccines
Chodick G, Tene L, Patalon T, Gazit S, Tov A Ben, Cohen D, et al. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization. Jama Netw Open. 2021;4(6):2–10.
Zhang Y, Zeng G, Pan H, Li C, Kan B, Hu Y, et al. Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial. Medrix. 2020;
Glampson B, Brittain J, Kaura A, Mulla A, Mercuri L, Brett SJ, et al. Assessing Covid-19 Vaccine Uptake and Effectiveness Through The North West London Vaccination Program: Retrospective Cohort Study. JMIR Public Heal Surveill [Internet]. 2021;7(9):1–17. Available from: https://publichealth.jmir.org/2021/9/e30010
Berec L, Smid M, Pribylova L, Majek O, Pavlik T, Jarkovsky J, et al. Real-Life Protection Provided by Vaccination, Booster Doses And Previous Infection Against Covid-19 Infection, Hospitalisation or Death Over Time In The Czech Republic: A Whole Country Retrospective View. medRxiv [Internet]. 2021;2021.12.10.21267590. Available from: http://medrxiv.org/content/early/2021/12/12/2021.12.10.21267590.abstract
World Health Organization. Status of COVID-19 Vaccines within WHO EUL/PQ Evaluation Process (11 November 2021) [Internet]. World Health Organization. 2021. Available from: https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_11Nov2021.pdf
World Health Organization. Interim Recommendations for Use of the Inactivated COVID-19 Vaccine, CoronaVac, Developed by Sinovac [Internet]. World Health Organization. 2021. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-Sinovac-CoronaVac-2021.1
El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med. 2021;385(19):1774–85.
Kaur SP, Gupta V. COVID-19 Vaccine: A Comprehensive Status Report. Virus Res. 2020;288(January):13.
Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. Effect of Vaccination on Household Transmission of SARS-CoV-2 in England. N Engl J Med. 2021;385(8):759–60.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-Non Commercial License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
The content of this website is licensed under a Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA 4.0) license. 
